- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.03. | FDA's CRLs reveal critical errors in AstraZeneca's Saphnelo data, efficacy doubts for GSK's Exdensur | ||
| 03.03. | Disc lays off 20% of employees to steady ship after FDA rejection of rare disease drug | ||
| 03.03. | Novo plugs $500M into Ireland plant to produce Wegovy pill for markets outside US | ||
| 03.03. | Esperion pays $75M-plus to acquire Corstasis and newly approved Enbumyst | ||
| 02.03. | 'One2PrEP': Gilead's 1st Yeztugo DTC ad reimagines hit song to highlight biannual dosing | ||
| 02.03. | Regulatory tracker: Novo Nordisk, BioMarin gain FDA label expansions | ||
| 02.03. | Amid unfolding Middle East war, pharma giants keep close eye on employee safety, supply chains | ||
| 02.03. | Kennedy adds 2 new members to CDC's vaccine panel ahead of delayed meeting | ||
| 02.03. | CDMO Quotient extends Ipsen supply pact for rare disease drug Sohonos | ||
| 02.03. | Bavarian Nordic CEO to follow board chair out the door after failed private equity takeover | ||
| 02.03. | Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel | ||
| 27.02. | Merck to wind down Gardasil production at N.C. plant, lay off 150-plus | ||
| 27.02. | Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle | ||
| 27.02. | Sanofi, Genentech, Kedrion back star-studded bleeding disorder awareness campaign | ||
| 27.02. | After CHMP nod, Moderna CEO applauds EU's 'rigorous scientific review' | ||
| 27.02. | UCB's fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum builds | ||
| 27.02. | As SCOTUS takes on 'skinny label' review, top US lawyer sides with generics maker | ||
| 27.02. | Fierce Pharma Asia-China deal growth; Daiichi's new CMO; Astellas-Vir bispecific tie-up | ||
| 27.02. | Autoimmune CAR-T:'¯Navigating the FDA's new regulatory playbook | ||
| 26.02. | Boehringer's Hernexeos secures speedy first-line expansion in FDA's 2nd national priority nod | ||
| 26.02. | After delay, CDC vaccine panel sets new dates to discuss long COVID and mRNA shot safety | ||
| 26.02. | OMG-argenx scores again with Vyvgart in ocular myasthenia gravis | ||
| 26.02. | Eisai points the way to kidney cancer support with Kompass digital hub | ||
| 26.02. | Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies | ||
| 26.02. | Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.